AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

To join this study, you need to be at least 18 years old and your cancer cells must show a specific marker called CLDN18.2. You should also be generally well enough to take part, meaning you can mostly look after yourself and have a good predicted life expectancy. Your body's organs, like your kidneys and liver, need to be working well, and you must weigh more than 35 kg.

Beyond these general rules, there are specific requirements depending on your cancer type. For stomach or gastroesophageal junction cancer, you must have advanced disease and have had no more than two previous treatments for it. For pancreatic cancer, you can't have had any prior treatment for your advanced disease, but previous chemotherapy before your cancer spread is allowed if it was more than six months ago. For bile duct cancer, you need to have already had at least one treatment, but no more than two, and your cancer must have progressed despite those treatments.

There are also reasons why you might not be able to join, such as having certain other serious health conditions like active stomach ulcers or digestive bleeding. It's important to discuss your full medical history with the study team to see if you meet all the criteria.

If you decide to take part, you will be given the study medicine, AZD0901, through a drip into your vein (intravenously). Depending on which part of the study you join, you might receive AZD0901 on its own or together with other cancer medicines. The study will involve regular visits to the hospital for these treatments, and doctors will perform various tests and assessments to monitor your health and how you respond to the treatment. This includes blood tests, scans, and physical examinations. The exact number of visits and the full duration of your participation will depend on how your treatment progresses and what part of the study you are in, but the team will explain everything to you in detail. You will be closely monitored throughout the study and during any follow-up period.